The KDR-KO significantly reduced SW579 sprouts formation in vitro, confirming that including selective targeting of KDR to anti-cancer therapy to suppress the VEGF/VEGFR axis in patients with clinical advanced thyroid cancers might increase its efficacy [142]. This evidence concerns the gene KDR and thyroid gland carcinoma.